In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

ARCA biopharma, Inc.. Trade Record

NASDAQ:ABIO ARCA biopharma, Inc. stock gains 6.85% Exit Sep 17, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ABIO Sep 9, 2019, priceSeries
About ARCA biopharma, Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Trade Information
Trade Type
Entry Date
Sep 9, 2019
Entry Price
Sell Date
Sep 17, 2019
Sell Price
Net Gain
Hold Time
6 Trading Days